User profiles for David Montani
David MONTANIProfessor of Respiratory Medicine, Université Paris–Saclay, AP-HP, INSERM UMR_S 999 … Verified email at aphp.fr Cited by 33285 |
[HTML][HTML] Haemodynamic definitions and updated clinical classification of pulmonary hypertension
G Simonneau, D Montani… - European respiratory …, 2019 - Eur Respiratory Soc
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥…
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥…
[HTML][HTML] Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial
…, P Tissieres, M Jevnikar, D Montani… - JAMA internal …, 2021 - jamanetwork.com
Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
Background— Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …
hypertension. We conducted a study to characterize mortality in a multicenter prospective cohort of …
Four-month clinical status of a cohort of patients after hospitalization for COVID-19
Importance Little is known about long-term sequelae of COVID-19. Objective To describe
the consequences at 4 months in patients hospitalized for COVID-19. Design, Setting, and …
the consequences at 4 months in patients hospitalized for COVID-19. Design, Setting, and …
[HTML][HTML] A novel channelopathy in pulmonary arterial hypertension
…, EB Rosenzweig, B Girerd, D Montani… - … England Journal of …, 2013 - Mass Medical Soc
Background Pulmonary arterial hypertension is a devastating disease with high mortality.
Familial cases of pulmonary arterial hypertension are usually characterized by autosomal …
Familial cases of pulmonary arterial hypertension are usually characterized by autosomal …
Pulmonary arterial hypertension in patients treated by dasatinib
D Montani, E Bergot, S Günther, L Savale, A Bergeron… - Circulation, 2012 - Am Heart Assoc
Background— The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension
M Eyries, D Montani, B Girerd, C Perret, A Leroy… - Nature …, 2014 - nature.com
Pulmonary veno-occlusive disease (PVOD) is a rare and devastating cause of pulmonary
hypertension that is characterized histologically by widespread fibrous intimal proliferation of …
hypertension that is characterized histologically by widespread fibrous intimal proliferation of …
[HTML][HTML] Sotatercept for the treatment of pulmonary arterial hypertension
…, J Feldman, G Meyer, D Montani… - … England Journal of …, 2021 - Mass Medical Soc
Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?
A Huertas, D Montani, L Savale… - European …, 2020 - Eur Respiratory Soc
Coronavirus disease 2019 (COVID-19) represents a public health crisis of pandemic
proportions. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …
proportions. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the …